Table 3 Subgroup analysis of the diagnostic efficacy of lncRNA in stomach cancer
Group | Subgroup | No. of studies | No. of patients | Sensitivity | Heterogeneity (I2, P value) | Specificity | Heterogeneity (I2, P value) | AUC | Meta-regression (P value) |
|---|---|---|---|---|---|---|---|---|---|
Overall |  | 42 | 7524 | 0.78 [0.75, 0.81] | 88.93%; <0.001 | 0.75 [0.71, 0.78] | 88.14%; <0.001 | 0.83 [0.80–0.86] |  |
Race | Asian | 60 | 7090 | 0.78 [0.75, 0.81] | 89.38%; <0.001 | 0.74 [0.70, 0.77] | 87.51%; <0.001 | 0.83 [0.79–0.86] | 0.48 |
Caucasian | 5 | 434 | 0.81 [0.70, 0.89] | 75.16%; <0.001 | 0.86 [0.52, 0.97] | 94.22%; <0.001 | 0.87 [0.84–0.90] | 0.48 | |
Pathologic types (E) | GC | 60 | 6936 | 0.78 [0.74, 0.81] | 88.19%; <0.001 | 0.75 [0.71, 0.79] | 88.35%; <0.001 | 0.83 [0.80–0.86] | 0.38 |
EGC | 5 | 588 | 0.85 [0.72, 0.93] | 91.39%; <0.001 | 0.71 [0.58, 0.81] | 90.27%; <0.001 | 0.84 [0.80–0.87] | 0.38 | |
Pathologic types (C) | health | 61 | 6549 | 0.79 [0.75, 0.82] | 89.32%; <0.001 | 0.75 [0.71, 0.79] | 86.53%; <0.001 | 0.84 [0.80–0.87] | 0.15 |
non-GC | 2 | 212 | – | – | – | – | – | 0.86 | |
GS | 2 | 763 | – | – | – | – | – | 0.10 | |
Sample size | N≤100 | 21 | 1153 | 0.79 [0.74, 0.84] | 74.67%; <0.001 | 0.77 [0.69, 0.84] | 84.82%; <0.001 | 0.85 [0.82–0.88] | 0.62 |
100<N≤200 | 28 | 2722 | 0.79 [0.74, 0.82] | 79.14%; <0.001 | 0.74 [0.68, 0.79] | 85.75%; <0.001 | 0.83 [0.80–0.86] | 0.95 | |
N>200 | 16 | 3649 | 0.77 [0.68, 0.84] | 95.41%; <0.001 | 0.73 [0.65, 0.79] | 92.57%; <0.001 | 0.81 [0.77–0.84] | 0.58 | |
Specimen | Plasma | 23 | 3467 | 0.78 [0.74, 0.82] | 87.25%; <0.001 | 0.72 [0.67, 0.77] | 86.87%; <0.001 | 0.82 [0.79–0.85] | 0.34 |
Serum | 12 | 2468 | 0.78 [0.72, 0.83] | 90.56%; <0.001 | 0.75 [0.67, 0.82] | 90.37%; <0.001 | 0.84 [0.80–0.87] | 0.99 | |
Exosome | 8 | 1589 | 0.81 [0.70, 0.89] | 92.18%; <0.001 | 0.81 [0.76, 0.86] | 69.40%; <0.001 | 0.87 [0.84–0.90] | 0.17 | |
Dysregulated state | Upregulated | 46 | 6003 | 0.78 [0.74, 0.82] | 90.19%; <0.001 | 0.75 [0.71, 0.80] | 87.40%; <0.001 | 0.84 [0.80–0.87] | 0.78 |
Downregulated | 19 | 1521 | 0.79 [0.72, 0.84] | 84.54%; <0.001 | 0.72 [0.64, 0.79] | 89.12%; <0.001 | 0.82 [0.79–0.86] | 0.78 | |
lncRNA | H19 | 7 | 848 | 0.78 [0.70, 0.84] | 75.98%; <0.001 | 0.72 [0.49, 0.88] | 89.62%; <0.001 | 0.82 [0.78–0.85] | 0.69 |
UCA1 | 3 | 361 | 0.87 [0.81, 0.91] | 83.60%; 0.02 | 0.82 [0.76, 0.88] | 45.20%; 0.161 | 0.92 [0.84–0.99] | 0.13 | |
CEBPA-AS1 | 3 | 564 | 0.77 [0.73, 0.81] | 86.00%; 0.001 | 0.76 [0.69, 0.82] | 86.80%; 0.001 | 0.88 [0.84–0.92] | 0.63 |